Clinical Trial Update: Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of glufosfamide in patients with recurrent sensitive small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Glufosfamide (glufosfamide)

Snippet

Sponsor: Threshold Pharmaceuticals | Conditions: Carcinoma, Small Cell Lung | Phase 2 | Status: TERMINATED